ORIENTBIO Inc. - Asset Resilience Ratio
ORIENTBIO Inc. (002630) has an Asset Resilience Ratio of 32.60% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ORIENTBIO Inc. working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2025)
This chart shows how ORIENTBIO Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see ORIENTBIO Inc. asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down ORIENTBIO Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore ORIENTBIO Inc. long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩26.20 Billion | 32.6% |
| Total Liquid Assets | ₩26.20 Billion | 32.60% |
Asset Resilience Insights
- Very High Liquidity: ORIENTBIO Inc. maintains exceptional liquid asset reserves at 32.60% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ORIENTBIO Inc. Industry Peers by Asset Resilience Ratio
Compare ORIENTBIO Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH |
Biotechnology | 63.98% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 62.24% |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA |
Biotechnology | 0.00% |
|
Wecome Pharmaceutical Co Ltd
SHE:300878 |
Biotechnology | 0.67% |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX |
Biotechnology | 86.66% |
|
Relmada Therapeutics Inc
NASDAQ:RLMD |
Biotechnology | 95.25% |
|
MediWound Ltd
F:M8W |
Biotechnology | 56.04% |
Annual Asset Resilience Ratio for ORIENTBIO Inc. (2006–2025)
The table below shows the annual Asset Resilience Ratio data for ORIENTBIO Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 30.67% | ₩26.00 Billion ≈ $17.62 Million |
₩84.78 Billion ≈ $57.46 Million |
-5.54pp |
| 2024-03-31 | 36.21% | ₩35.12 Billion ≈ $23.80 Million |
₩96.99 Billion ≈ $65.73 Million |
-0.23pp |
| 2023-03-31 | 36.44% | ₩29.53 Billion ≈ $20.01 Million |
₩81.05 Billion ≈ $54.93 Million |
+8.76pp |
| 2022-03-31 | 27.68% | ₩29.05 Billion ≈ $19.69 Million |
₩104.95 Billion ≈ $71.12 Million |
+26.56pp |
| 2021-03-31 | 1.12% | ₩800.00 Million ≈ $542.15K |
₩71.52 Billion ≈ $48.47 Million |
+0.01pp |
| 2020-03-31 | 1.11% | ₩801.00 Million ≈ $542.83K |
₩72.11 Billion ≈ $48.86 Million |
+0.04pp |
| 2019-03-31 | 1.07% | ₩901.53 Million ≈ $610.96K |
₩84.09 Billion ≈ $56.99 Million |
-5.57pp |
| 2018-03-31 | 6.64% | ₩12.62 Billion ≈ $8.55 Million |
₩190.03 Billion ≈ $128.78 Million |
+5.47pp |
| 2017-03-31 | 1.17% | ₩2.02 Billion ≈ $1.37 Million |
₩172.63 Billion ≈ $116.99 Million |
+0.45pp |
| 2016-03-31 | 0.72% | ₩1.27 Billion ≈ $862.71K |
₩175.64 Billion ≈ $119.03 Million |
-3.44pp |
| 2015-03-31 | 4.16% | ₩6.19 Billion ≈ $4.20 Million |
₩148.76 Billion ≈ $100.82 Million |
-4.13pp |
| 2014-03-31 | 8.30% | ₩11.58 Billion ≈ $7.85 Million |
₩139.63 Billion ≈ $94.63 Million |
-0.80pp |
| 2013-03-31 | 9.10% | ₩12.39 Billion ≈ $8.40 Million |
₩136.24 Billion ≈ $92.33 Million |
-6.51pp |
| 2012-03-31 | 15.61% | ₩19.29 Billion ≈ $13.07 Million |
₩123.55 Billion ≈ $83.73 Million |
-3.39pp |
| 2011-03-31 | 19.00% | ₩16.12 Billion ≈ $10.92 Million |
₩84.86 Billion ≈ $57.51 Million |
+4.22pp |
| 2010-03-31 | 14.77% | ₩15.41 Billion ≈ $10.44 Million |
₩104.31 Billion ≈ $70.69 Million |
+0.69pp |
| 2009-03-31 | 14.08% | ₩13.82 Billion ≈ $9.37 Million |
₩98.18 Billion ≈ $66.53 Million |
-1.31pp |
| 2008-03-31 | 15.39% | ₩12.73 Billion ≈ $8.63 Million |
₩82.72 Billion ≈ $56.06 Million |
+10.26pp |
| 2007-03-31 | 5.13% | ₩3.74 Billion ≈ $2.53 Million |
₩72.88 Billion ≈ $49.39 Million |
-13.29pp |
| 2006-03-31 | 18.42% | ₩12.56 Billion ≈ $8.51 Million |
₩68.17 Billion ≈ $46.20 Million |
-- |
About ORIENTBIO Inc.
ORIENT BIO Inc. operates in the bio-industry in South Korea and internationally. It engages in the production, export, import, and life science-related research and development of laboratory animals; and offers various equipment for research environment. The company also provides infrastructural solution; health checking; generic testing; molecular biological generic testing; generic transformati… Read more